- Home
- EMKR vs PSTV Comparison
EMKR vs PSTV Comparison
Compare EMKR & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMKR
- PSTV
- Stock Information
- Founded
- EMKR 1984
- PSTV 1996
- Country
- EMKR United States
- PSTV United States
- Employees
- EMKR N/A
- PSTV N/A
- Industry
- EMKR Semiconductors
- PSTV Medical/Dental Instruments
- Sector
- EMKR Technology
- PSTV Health Care
- Exchange
- EMKR Nasdaq
- PSTV Nasdaq
- Market Cap
- EMKR 9.5M
- PSTV 9.4M
- IPO Year
- EMKR 1997
- PSTV N/A
- Fundamental
- Price
- EMKR $2.33
- PSTV $1.40
- Analyst Decision
- EMKR Buy
- PSTV Strong Buy
- Analyst Count
- EMKR 2
- PSTV 2
- Target Price
- EMKR $3.00
- PSTV $14.00
- AVG Volume (30 Days)
- EMKR 2.0M
- PSTV 86.1K
- Earning Date
- EMKR 12-10-2024
- PSTV 10-29-2024
- Dividend Yield
- EMKR N/A
- PSTV N/A
- EPS Growth
- EMKR N/A
- PSTV N/A
- EPS
- EMKR N/A
- PSTV N/A
- Revenue
- EMKR $90,961,000.00
- PSTV $5,509,000.00
- Revenue This Year
- EMKR N/A
- PSTV $11.13
- Revenue Next Year
- EMKR $7.07
- PSTV N/A
- P/E Ratio
- EMKR N/A
- PSTV N/A
- Revenue Growth
- EMKR 413.79
- PSTV 113.20
- 52 Week Low
- EMKR $0.78
- PSTV $0.97
- 52 Week High
- EMKR $7.20
- PSTV $2.78
- Technical
- Relative Strength Index (RSI)
- EMKR 67.47
- PSTV 48.32
- Support Level
- EMKR $2.07
- PSTV $1.20
- Resistance Level
- EMKR $2.54
- PSTV $1.45
- Average True Range (ATR)
- EMKR 0.16
- PSTV 0.11
- MACD
- EMKR -0.02
- PSTV 0.01
- Stochastic Oscillator
- EMKR 55.32
- PSTV 66.67
About EMKR EMCORE Corporation
EMCORE Corp is a provider of sensors and navigation systems for the aerospace and defense market. The company operates in one reporting segment, Inertial Navigation, whose product technology categories include: (a) FOG, (b) QMEMS, (c) RLG, in each case which serve the aerospace and defense market. The company operates geographically in United States and Canada, which is the key revenue generator; Asia; Europe; and Other.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).